A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
Status:
Completed
Trial end date:
2016-11-09
Target enrollment:
Participant gender:
Summary
VT-1161 is a novel, oral inhibitor of fungal lanosterol demethylase (CYP51). In vitro and in
vivo pharmacology studies have demonstrated that VT-1161 is highly active against Candida
albicans and also non-albicans Candida species that cause vulvovaginal candidiasis. VT-1161
is highly selective for fungal CYP51, and data suggests that it may avoid the side-effect
profile that limits the use of commonly prescribed antifungal agents for the treatment of
recurrent yeast infections.